The participants constitute over 15% of the adult population of Iceland, and the timing of the sample collection, regarding cancer onset, diagnosis and progression, is unlikely to have a major impact on the GWAS of ADAM17 [11,13]. The gene discussed is ADAM17; the disease is cancer.